Business Context and Reporting Period
Company: MYOMO, INC. (MYO)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2026
Business Overview: Myomo is a wearable medical robotics company developing myoelectric orthotics (MyoPro) for patients with neuromuscular disorders. The company operates as a single segment, selling directly to patients (direct billing), to Orthotics and Prosthetics (O&P) providers, and to the Veterans Health Administration (VA). Revenue is heavily concentrated in the U.S. market (80%) with significant reliance on Medicare Part B reimbursement (51% of revenue).
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $10,113,288 | $9,831,814 |
| Gross Profit | $6,901,606 | $6,609,630 |
| Gross Margin | 68.2% | 67.2% |
| Net Loss | $(3,009,399) | $(3,465,058) |
| Loss Per Share (Basic/Diluted) | $(0.07) | $(0.08) |
| Operating Cash Flow | $(2,197,336) | $(2,676,899) |
| Cash & Equivalents (End of Period) | $11,396,426 | $14,132,027 |
| Short-Term Investments | $4,299,978 | $4,261,782 |
| Total Liquidity | $15,696,404 | $18,393,809 |
| Long-Term Debt (Net) | $10,926,208 | $11,222,155 |
| Working Capital | $16,272,798 | $19,211,756 |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 3% year-over-year to $10.1 million, driven by a higher average selling price (ASP) due to CMS inflationary adjustments and increased international revenue.
- Expense Management: Total operating expenses decreased slightly by 1% to $10.1 million. Research and Development (R&D) expenses fell 9% due to lower labor costs, while Selling, Clinical, and Marketing (SC&M) expenses rose 10% due to increased advertising and new clinical sales personnel.
- Net Loss Improvement: Net loss narrowed by approximately $456,000 (13%) compared to Q1 2025. This improvement was significantly aided by a non-cash gain of $839,064 from the change in fair value of derivative liabilities.
- Debt Restructuring: In November 2025, the company secured a $17.5 million term loan facility with Avenue Capital Management, repaying its previous Silicon Valley Bank credit facility. The company is currently in an interest-only period on this new debt.
Guidance, Outlook, and Risks
Management Commentary and Strategy
Management plans to pivot away from reliance on direct-to-patient advertising toward recurring revenue sources, specifically expanding the "MyoConnect" referral program in rehab clinics and growing the O&P channel in the U.S. and Germany. The goal is to reduce the "Cost Per Pipeline Add" and minimize fixed expense growth to achieve cash flow breakeven.
Liquidity Outlook
Based on current cash, cash equivalents, and short-term investments totaling approximately $15.7 million, management believes the company has sufficient liquidity to fund operations for at least the next 12 months.
Risks and Contingencies
- Reimbursement Dependence: Significant revenue concentration with Medicare Part B (51%) and Medicare Advantage (18%) creates exposure to changes in reimbursement policies and rates.
- China Joint Venture: The company's Chinese joint venture partner, Ryzur Medical, filed for bankruptcy in November 2025. Operations are severely limited, though the company notes no financial impact as assets were previously written off.
- Derivative Liabilities: The company holds significant derivative liabilities ($1.8 million total) related to its debt and warrants, which fluctuate based on stock price and volatility, impacting reported net income.
- Trade and Tariffs: Potential escalation of tariffs on imports from China could impact gross margins, though currently estimated to be less than 100 basis points.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the current operating cash burn (~$2.2M per quarter) against the $15.7M liquidity position and the $5M remaining tranche of the Avenue loan.
- Reimbursement Stability: Monitor CMS payment determinations and any changes to Medicare Advantage pre-authorization requirements, given the 69% combined revenue concentration.
- Derivative Liability Volatility: Assess the impact of stock price fluctuations on the $1.8M derivative liability, which currently provides a non-cash gain masking the operational loss.
- China JV Resolution: Track the restructuring efforts of the China joint venture to determine if the company will terminate the agreement or if it poses future operational risks.
- Marketing Efficiency: Evaluate the success of the "MyoConnect" program in reducing the Cost Per Pipeline Add as the company shifts strategy away from direct advertising.